Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tracking lung scarring: new registry aims to map progressive pulmonary fibrosis in china

NCT ID NCT07683728

Recruiting now Knowledge-focused Sponsor: Zuojun Xu Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study follows 600 people in China with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Researchers will measure changes in lung function over two years and analyze patients' characteristics, treatments, and needs. The goal is to better understand how PPF progresses in real-world settings and identify gaps in current care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could reveal how progressive pulmonary fibrosis evolves in Chinese patients and highlight gaps in current care.
What could go wrong
As an observational registry, it does not test any treatment, so it cannot directly improve outcomes. Results may not apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE PULMONARY FIBROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.